NEW YORK, Nov. 19, 2012 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p01041701/Parenteral-Nutrition-Market-to-2018---Rising-Incidence-of-Chronic-Diseases-such-as-Cancer-AIDS-and-Gastrointestinal-GI-Disorders-and-Increased-Use-of-Specialty-Drugs-Drive-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Parenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs Drive Growth

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The PN market is rapidly growing with the increasing incidence of diseases such as cancer, AIDS and GI disorders including short bowel syndrome, ischemic bowel disease, pseudo obstruction and Crohn's disease. The other major factor driving growth of the PN market is an increase in the elderly population in the developed countries. In 2011, the global PN market was estimated to be worth $2.9 billion, representing a CAGR of 6.3% between 2004 and 2011. The US market, with sales worth $1,476m in 2011, accounted for 50.7% of the total PN market. The market in the top five countries in Europe was estimated to be $1,275m, the second largest PN market, and to have grown at a CAGR of 5.4% between 2004 and 2011. The PN market in Japan registered a share of 5.4% of the total PN market, accounting for $157m sales value in 2011.

By 2018, the PN market is forecast to be worth $4,861m, representing a CAGR of 7.6% between 2011 and 2018. The US is expected to remain the largest segment in the PN market with $2,492m of sales in 2018. The PN market in the top five countries in Europe will be the second largest segment with $2,104m in revenues in 2018. Japan, which was the smallest segment in 2011, is expected to register sales value of $265m in 2018, indicating a CAGR of 7.8% between 2011 and 2018. The PN market M&A landscape demonstrated a fairly moderate level of activity between 2004 and 2010, with seven major acquisition deals signed during the time period.

Scope

- Annualized market data for the PN market from 2004 to 2011, forecast forward to 2018.- Analysis of the PN market in the leading geographies of the world, which include the US, the top five countries in Europe (the UK, Germany, France, Italy, Spain) and Japan. - Market segmentation of the PN market which includes the amino acid, lipids, carbohydrates and additives market in the leading geographies.- Key drivers and barriers that have a significant impact on the market. - Competitive benchmarking of the leading companies. The key companies studied in this report are Baxter, B. Braun, Fresenius Kabi, Hospira, Otsuka Pharmaceutical Factory, Terumo Corporation and Ajinomoto.- Key M&A activities, licensing agreements that have taken place between 2004 and 2011 in the global PN market.

Reasons to buy

- Develop market-entry and market expansion strategies by identifying the leading geographic markets poised for strong growth.- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class products with more efficiency and better safety.- Develop key strategic initiatives by understanding the key focus areas of leading companies. - Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.1 Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 82 Parenteral Nutrition Market to 2018 - Introduction 93 Parenteral Nutrition Market to 2018 - Overview 103.1 Clinical Nutrition 103.1.1 Enteral Nutrition 113.1.2 Parenteral Nutrition 114 Parenteral Nutrition Market to 2018 - Market Characterization and Forecasts 154.1 Revenue Forecasts 154.2 Parenteral Nutrition Market Drivers 164.2.1 Increase in the Incidence of Diseases such as Cancer, AIDS and GI Disorders that Require Nutrition Support 174.2.2 Increase in the Elderly Population will Drive PN Market Growth 174.2.3 The Home Parenteral Nutrition Sector will Witness Strong Market Growth 174.3 Parenteral Nutrition Market Restraints 174.3.1 Reimbursement Regulations will Hinder Market Growth in the US 174.3.2 Increasing Preference for Enteral Nutrition will Restrain Market Growth 174.3.3 Increasing Preference for Multi-chamber Bags Decreases Cost of Therapy 185 Parenteral Nutrition Market to 2018 - Geographical Landscape 195.1 Revenues by Geographical Segmentation 195.2 The US 215.2.1 Sales Value 215.2.2 Nutrient Market Segmentation 225.2.3 Key Products 225.3 Top Five Countries in Europe 235.3.1 Sales Value 235.3.2 Nutrient Market Segmentation 245.3.3 Key Products 245.4 Japan 255.4.1 Sales Value 255.4.2 Nutrient Market Segmentation 265.4.3 Key Products 266 Parenteral Nutrition Market to 2018 - Nutrient Market Segmentation 276.1 Overview 276.2 Amino Acids Market 286.2.1 Global Sales Value 286.2.2 Sales Value by Geography 286.3 Lipids Market 296.3.1 Global Sales Value 296.3.2 Sales Value by Geography 296.4 Carbohydrates Market 306.4.1 Global Sales Value 306.4.2 Sales Value by Geography 306.5 Additives Market 316.5.1 Global Sales Value 316.5.2 Sales Value by Geography 317 Parenteral Nutrition Market - Marketed Products 327.1 Baxter International Inc. 327.1.1 OLIMEL 327.1.2 Clinimix 337.1.3 ClinOleic 20% 347.1.4 Clinisol 15% 357.2 B. Braun Melsungen AG 367.2.1 NuTRIflex System 367.2.2 Lipofundin 377.2.3 Aminoplasmal 387.2.4 FreAmine III 397.3 Fresenius Kabi AG 407.3.1 Intralipid 407.3.2 SmofKabiven 417.3.3 Dipeptiven 427.3.4 Omegaven 437.4 Hospira, Inc. 447.4.1 Aminosyn 447.4.2 Liposyn 467.5 Otsuka Pharmaceutical Factory Inc. 477.5.1 Elneopa 477.5.2 Neoparen 477.5.3 B-Fluid 487.6 Terumo Corporation 497.6.1 Unicaliq 497.6.2 Fulcaliq 508 Parenteral Nutrition Market to 2018 - Competitive Landscape 518.1 Market Share Analysis: Parenteral Nutrition 518.2 Competitive Profiling 528.2.1 Baxter International Inc. 528.2.2 B. Braun Melsungen AG 548.2.3 Fresenius Kabi AG 568.2.4 Hospira, Inc. 588.2.5 Otsuka Pharmaceutical Factory Inc. 608.2.6 Terumo Corporation 619 Parenteral Nutrition Market to 2018 - Strategic Consolidations 629.1 Overview 629.2 Major Acquisitions in the Parenteral Nutrition Market 639.2.1 Baxter International Completes Acquisition of Prism Pharma for $338m in April 2011 639.2.2 Baxter Acquires Willow Healthcare Services in July 2009 639.2.3 Fresenius Acquires Novartis Nutrition and Nestle Espana in December 2007 639.2.4 Fresenius Kabi Acquires Infusia A.S. in December 2004 639.2.5 Fresenius Kabi Acquires Clinico GmbH in October 2005 639.2.6 Fresenius Kabi Acquires Isotec Nutrition from Alliance Pharmaceuticals in May 2004 639.2.7 Hospira Acquires Clayton Manufacturing Facility from Fresenius Kabi in June 2004 639.3 Major Agreements in the Parenteral Nutrition Market 649.3.1 Baxter Signs Agreement with Hanmi Pharmaceuticals in December 2010 649.3.2 Hospira Signs a Five-year Agreement with Novation in October 2010 649.3.3 B. Braun Signs Agreement with Amerinet Inc in October 2009 649.3.4 B. Braun Signs Agreement with Premier Purchasing Partners in August 2008 649.3.5 Hospira Announces New Contract with Premier Purchasing Partners in August 2008 659.3.6 Hospira Announces New Contract with HealthTrust Purchasing Group in February 2008 659.3.7 Baxter and Novation Sign Two-year Contract Extension in October 2007 659.3.8 Baxter Announces Plans to Form Parenteral Nutrition Joint Venture with Baiyunshan in China in August 2007 659.3.9 B. Braun Signs Agreement with Curlin Medical in March 2006 659.3.10 Freseniu
s Kabi and Pharmatel Pty Ltd. Formed a Joint Venture in September 2004 6610 Parenteral Nutrition Market to 2018 - Appendix 6710.1 Market Definitions 6710.2 Abbreviations 6710.3 Bibliography 6810.4 Research Methodology 6910.4.1 Coverage 6910.4.2 Secondary Research 6910.4.3 Primary Research 6910.4.4 Section Methodology 7010.4.5 Expert Panel Validation 7010.5 Contact Us 7010.6 Disclaimer 70

See the article here:
Parenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS and Gastrointestinal ...